Targeting NAD+ Synthesis to Potentiate CD38-Based Immunotherapy of Multiple Myeloma

Barry E Kennedy,Maryanne Sadek,Manal O Elnenaei,Anthony Reiman,Shashi A Gujar

DOI: https://doi.org/10.1016/j.trecan.2019.11.005

Abstract:Antibodies targeting CD38, a NAD+-degrading enzyme, have emerged as a promising immunotherapy against multiple myeloma (MM). Currently, the mechanisms by which anti-CD38 antibodies establish their therapeutic effects are poorly understood. Here, we advocate for the depletion of NAD+ to enhance the efficacy of anti-CD38-based immunotherapies in MM.